Announces Promotion of Dean Bunce to Vice President, Regulatory Affairs and Michael Wade
to Vice President, Development and Medical Affairs
...RESEARCH TRIANGLE PARK, N.C., Nov. 13 /PRNewswire-FirstCall/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today the promotions of Dean Bunce to Vice President of Regulatory Affairs and Michael Wade, Ph.D. to Vice President of Development and Medical Affairs.
...Dr. Wade joined United Therapeutics in 1997 and has nearly ten years of drug development experience; Dr. Wade has led project teams in all phases investigating multiple therapeutic areas.
Likewise, Dr. Wade
has been one of the key individuals responsible for the clinical development of Remodulin since its infancy, and is currently responsible for all post- approval studies of Remodulin, including the Phase IV Flolan transition study and the critical limb ischemia development effort."
will continue to be responsible for all post-marketing studies of Remodulin(R) (treprostinil sodium) Injection, United Therapeutics' therapy for the treatment of pulmonary arterial hypertension, and for progressing early stage compounds into and through clinical development.United Therapeutics
is a biotechnology company focused on combating cardiovascular, infectious and oncological diseases with unique therapeutic products.